References

1. 1.
   LI C，LI H.Treatment of IgA nephropathy in the era of evidence-based medicine and personalized medicine［J］.Chin Med J，2020，100（30）：2328-2331.
2. 2.
   LI L S，LIU Z H.Epidemiologic data of renal diseases from a single unit in China：Analysis based on 13，519 renal biopsies［J］.Kidney Int，2004，66（3）：920-923.
3. 3.
   TIAN X J，HUANG C.Research progress on pathogenesis of immune inflammation in IgA nephropathy［J］.Chin J Nephrol，2020，36（5）：400-405.
4. 4.
   TRIMARCHI H，BARRATT J，CATTRAN D C，et al.Oxford Classification of IgA nephropathy 2016：An update from the IgA Nephropathy Classification Working Group［J］.Kidney Int，2017，91（5）：1014-1021.
5. 5.
   MAIXNEROVA D，REILY C，BIAN Q，et al.Markers for the progression of IgA nephropathy［J］.J Nephrol，2016，29（4）：535-541.
6. 6.
   TRIMARCHI H，COPPO R.Podocytopathy in the mesangialprofierative immunoglulin A nephropathy：New insights into the mechanisms of damage and progression［J］.Nephrol Transplant，2019，34（8）：1280-1285.
7. 7.
   MAGISTRONI R，D'AGATI V D，APPEL G B，et al.New developments in the genetics，pathogenesis，and therapy of IgA nephropathy［J］.Kidney Int，2015，88（5）：974-989.
8. 8.
   LEUNG J，LAI K N，TANG S.Role of mesangial-podocytic-tubular cross-talk in IgA nephropathy［J］.Semin Nephrol，2018，38（5）：485-495.
9. 9.
   NAGATA M.Podocyte injury and its consequences［J］.Kidney Int，2016，89（6）：1221-1230.
10. 10.
    ZAMBRANO S，MÖLLER-HACKBARTH K，LI X，et al.GPRC5b modulates inflammatory response in glomerular diseases via NF-κB pathway［J］.J Am Soc Nephrol，2019，30（9）：1573-1586.
11. 11.
    CHENG Q，PAN J，ZHOU Z L，et al.Caspase-11/4 and gasdermin D-mediated pyroptosis contributes to podocyte injury in mouse diabetic nephropathy［J］.Acta Pharmacol Sin，2021，42（6）：954-963.
12. 12.
    SONG R J，ZHANG X X，GAO F，et al.Effects of Jiawei Shengjiangsan（加味升降散）on TXNIP/NLRP3 pathway and podocyte pyroptosis in rats with diabetic kidney disease［J］.Pharmacol Clin Chin Mater Med，2022，38（4）：2-9.
13. 13.
    LIU Y F，CHEN B M，HU X Q，et al.Clinical research of tongluo baoshen prescription on tubulointerstitial injury in IgA nephropathy［J］.Chin Med Mod Dist Edu China，2016，14（22）：58-60.
14. 14.
    LIU Y F，CHEN B M，HU X Q，et al.Clinical study of Tongluo Baoshen decoction in the treatment of IgA nephropathy［J］.Chin J Integr Tradit West Nephrol，2016，17（11）：991-993.
15. 15.
    SHEN Y J.Pharmacology of Traditional Chinese Medicine［M］.Beijing：People's Medical Publishing House，2004.
16. 16.
    Kidney Disease Committee of Chinese Society of Integrated Traditional Chinese and Western Medicine.Practice guide for western medicine diagnosis and TCM syndrome differentiation of IgA nephropathy［J］.Chin J Integr Med，2013，33（5）：583-585.
17. 17.
    LIU Y F，LIU H Y，CHEN B M，et al.TCM treatment of podocyte injury in IgA nephropathy based on multiple TCM theories：A review［J］.Chin J Exp Tradit Med Form，2024，30（4）：198-208.
18. 18.
    CAO H，LIANG J，LIU J，et al.Novel effects of combination therapy through inhibition of Caspase-1/Gasdermin D induced-pyroptosis in lupus nephritis［J］.Front Immunol，2021，12：720877.
19. 19.
    WANG S，LI Y，FAN J，et al.Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation［J］.Cell Death Dis，2017，8（7）：e2937.
20. 20.
    ZHANG P C.Salvianolic acid-B regulates pyroptosis by the Nrf2 in Acute kidney injury［D］.Guangzhou：Guangzhou University of Chinese Medicine，2019.
21. 21.
    PENG W，PEI G Q，TANG Y，et al.IgA1 deposition may induce NLRP3 expression and macrophage transdifferentiation of podocyte in IgA nephropathy［J］.J Transl Med，2019，17（1）：406.
22. 22.
    ZHANG H，WANG Z.Effect and regulation of the NLRP3 inflammasome during renal fibrosis［J］.Front Cell Dev Biol，2019，7：379.
23. 23.
    XIAO Y，HE H D，HU P，et al.Correlation between serum Gd-IgAl level and clinical and pathological characteristics of patients with IgA nephropathys［J］.J Clin Transfus Lab Med，2021，23（4）：492-496.
24. 24.
    CHEN F F，TANG H Y，YU F，et al.Renal involvement in a silicosis patient - Case report and literature review［J］.Ren Fail，2019，41（1）：1045-1053.
25. 25.
    YARIBEYGI H，MOHAMMADI M T，REZAEE R，et al.Fenofibrate improves renal function by amelioration of NOX-4，IL-18，and p53 expression in an experimental model of diabetic nephropathy［J］.J Cell Biochem，2018，119（9）：7458-7469.
26. 26.
    FU Q，WU J，ZHOU X Y，et al.NLRP3/Caspase-1 pathway-induced pyroptosis mediated cognitive deficits in a mouse model of sepsis-associated encephalopathy［J］.Inflammation，2019，42（1）：306-318.
27. 27.
    CHUN J，CHUNG H，WANG X，et al.NLRP3 localizesto the tubular epithelium in human kidney and correlates with outcome in IgA nephropathy［J］.Sci Rep，2016，6：24667.
28. 28.
    NAVARRO-GONZÁLEZ J F，MORA-FERNÁNDEZ C，MUROS DE FUENTES M，et al.Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy［J］.Nat Rev Nephrol，2011，7（6）：327-340.
29. 29.
    BOINI K M，XIA M，ABAIS J M，et al.Activation of inflammasomes in podocyte injury of mice on the high fat diet：Effects of ASC gene deletion and silencing［J］.Biochim Biophys Acta，2014，1843（5）：836-845.
30. 30.
    LIANG J，ZHANG Y，CAO L，et al.The effect of fibrinolytic system on podocyte injury in membranous nephropathy rats［J］.Acta Lab Anim Sci Sin，2016，24（3）：283-287.
31. 31.
    HAN W W.α₃β₁ integrin and podocyte lesion［J］.Int J Urol Nephrol，2015，35（5）：787-790.
32. 32.
    ZHANG L，LIU W，LI S，et al.Astragaloside Ⅳ alleviates renal fibrosis by inhibiting renal tubular epithelial cell pyroptosis induced by urotensin Ⅱ through regulating the cAMP/PKA signaling pathway［J］.PLoS One，2024，19（5）：e0304365.